Evidence map›Paper›PMID 32212056›Full record

ArticleJournal of bioethical inquiry2020

Commentary: The Voice of the People, Funded Now by Your Friendly Pharmaceutical Company.

Ray Moynihan

Abstract readComment
PubMed Publisher
In one paragraph

Article in Journal of bioethical inquiry, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Lead Essay: Money, Equity and Access to Medicines.Journal of bioethical inquiry · 2020
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

1 author.

Ray MoynihanBond University, Gold Coast, Australia. rmoyniha@bond.edu.au.

Funding

National Health and Medical Research Council 1124207
6 · The paper itself

Abstract

Pharmaceutical industry funding has transformed much grassroots community activism on health into corporate-sponsored advocacy. This critical commentary outlines recent evidence about industry funding of patient advocacy groups, offers a commentary on the history of grassroots activism appearing in this issue of the journal, and calls for greater scrutiny of the impacts and ethics of such sponsorship.

Indexed as

Drug IndustryPharmaceutical PreparationsHumansPharmaceutical PreparationsCitizen health advocacyConflicts of interestPharmaceuticals

Identifiers

PMID32212056

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.